# EDGAR Filing Document

**Accession Number:** 0000842023
**File Stem:** 0000914190-26-000036
**Filing Date:** 2026-3
**Character Count:** 9571
**Document Hash:** 673cc2cff04fe089b5a7d9576b402db5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000036.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0000914190-26-000036

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260302

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Crouse Steven C.
- **CENTRAL INDEX KEY:** 0002065241

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 26723391

**MAIL ADDRESS:**
- **STREET 1:** 5980 HORTON STREET, STE 600
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Crouse Steven C.<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President - Diag & Spatial Bi_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 5894 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 1588 |  | 1588 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1800 |  | 1800 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1379 |  | 1379 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 3737 |  | 3737 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 6529 |  | 6529 | D |  |
| Stock Option (right to buy) | $97.13 |  |  |  |  |  |  | <sup>(7)</sup> | 2028-04-01 | Common Stock | 3856 |  | 3856 | D |  |
| Stock Option (right to buy) | $120.46 |  |  |  |  |  |  | <sup>(7)</sup> | 2028-08-06 | Common Stock | 19032 |  | 19032 | D |  |
| Stock Option (right to buy) | $94.52 |  |  |  |  |  |  | <sup>(8)</sup> | 2029-08-15 | Common Stock | 24560 |  | 24560 | D |  |
| Stock Option (right to buy) | $84.61 |  |  |  |  |  |  | <sup>(9)</sup> | 2030-08-15 | Common Stock | 12649 |  | 12649 | D |  |
| Stock Option (right to buy) | $73.46 |  |  |  |  |  |  | <sup>(10)</sup> | 2031-05-01 | Common Stock | 7327 |  | 7327 | D |  |
| Stock Option (right to buy) | $74.91 |  |  |  |  |  |  | <sup>(11)</sup> | 2034-08-15 | Common Stock | 17133 |  | 17133 | D |  |
| Stock Option (right to buy) | $48.61 |  |  |  |  |  |  | <sup>(12)</sup> | 2035-06-02 | Common Stock | 5434 |  | 5434 | D |  |
| Stock Option (right to buy) | $53.60 |  |  |  |  |  |  | <sup>(13)</sup> | 2035-08-15 | Common Stock | 19151 |  | 19151 | D |  |
| Performance Restricted Stock Units | <sup>(1)</sup> | 2026-03-02 |  | A |  | 2387 |  | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 2387 | $0 | 2387 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2026-03-02 |  | A |  | 735 |  | <sup>(15)</sup> | <sup>(15)</sup> | Common Stock | 735 | $0 | 735 | D |  |
| Stock Option (right to buy) | $57.82 | 2026-03-02 |  | A |  | 1911 |  | <sup>(16)</sup> | 2036-03-02 | Common Stock | 1911 | $0 | 1911 | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(2) 794 restricted stock units vest on 5/1/2026 and 5/1/2027.

(3) 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.

(4) 1,379 restricted stock units vest on 8/15/2026.

(5) 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.

(6) 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.

(7) 100% vested.

(8) Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

(9) Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

(10) Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

(11) Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

(12) Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

(13) Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

(14) Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(15) 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.

(16) Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed.  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**